Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Major subject (≥18 years old)
Suffering from relapsing-remitting MS (RRMS)
Supported in a neurology department at Strasbourg or Nancy University Hospital between 10/01/2018 and 11/31/2020.
Treated with ocrelizumab 600mg every 6 months during the period from 01/10/2018 to 01/05/2020.
Have had an M0, M3 / M6 and M12 MRI after initiation of treatment.
Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research
Impossibility of providing the subject with enlightened information (difficulties in understanding the subject, etc.)
Subjects under safeguard of justice
Subject under guardianship or guardianship

Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS